列线图
医学
逻辑回归
接收机工作特性
糖化血红素
内科学
曲线下面积
糖尿病
神经学
冲程(发动机)
临床试验
线性回归
多元统计
临床决策
物理疗法
风险评估
回归分析
作者
Song Zhang,Yue Hu,Weiye Wang,Hanxiao Zhou,Xiao Yu,Guangyu Zhang
标识
DOI:10.1186/s41983-026-01111-6
摘要
Abstract Objective To develop and validate a multiparameter-based nomogram for predicting early neurological deterioration (END) in patients with acute ischemic stroke (AIS), integrating serum biomarkers and clinical factors. Methods This retrospective study enrolled 505 AIS patients. The primaryoutcome was the occurrence of END. The least absolute shrinkage and selection operator (LASSO) regression was employed for variable selection from a comprehensive set of clinical characteristics and laboratory biomarkers. Significant predictors identified were incorporated into a multivariable logistic regression to construct the predictive nomogram. Model performance was assessed by discrimination (area under the receiver operating characteristic curve, AUC), calibration (calibration curve), and clinical utility (decision curve analysis). Internal validation was performed using the bootstrap resampling method. Results Among the 505 AIS patients, 89 (17.6%) experienced END. Thefinal nomogram incorporated six independent predictors: non-high-density lipoprotein cholesterol (Non-HDL-C), high-sensitivity C-reactive protein (hs-CRP), fibrinogen (FIB), history of diabetes mellitus, National Institutes of Health Stroke Scale (NIHSS) score at admission, and glycated hemoglobin (HbA1c). The model demonstrated excellent discrimination, with an AUC of 0.876 (95% CI 0.835–0.917). Calibration curve and decision curve analysis confirmed satisfactory model calibration and positive net clinical benefit, respectively. Internal validation yielded a corrected C-index of 0.859, indicating robust model performance. Conclusion We developed and validated a multiparameter nomogram that integrates lipid, inflammatory, coagulation, and clinical parameters for the individualized prediction of END risk in AIS patients. This practical tool may assist clinicians in early risk stratification and personalized management.
科研通智能强力驱动
Strongly Powered by AbleSci AI